Solupharm Limited

Pre-clinical MS Research using EAE models

Selected EAE-Related Publications

Bolton, C., Borel, J.F., Cuzner, M.L., Davison, A.N., Turner, A.M. (1982)
Immunosuppression by cyclosporin A of experimental allergic encephalomyelitis.
Neurol. Sci. 56 147-153

Bolton, C., Paul, C. (2006)
Glutamate receptors in neuroinflammatory demyelinating disease.
Med. Inflamm.

Bolton, C., O?Neill, J.K., Allen, S.J., Baker, D. (1997)
Regulation of chronic relapsing experimental allergic encephalomyelitis by endogenous and exogenous glucocorticoids.
Int. Arch. Allergy Immunol. 114 74-80.

Bolton, C., Scott, G.S., Smith, T., Flower, R.J. (2008)
The acute and chronic phases of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE) are ameliorated by the peroxynitrite decomposition catalyst, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrination (III) chloride, (FeTPPS).
Eur. J. Pharmacol. 601 88-93.

Bolton, C., Wood, E.G., Ayoub, S.S.
The N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801, influences prostaglandin levels in specific areas of the central nervous system during the relapse phase of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE).
Fund. Clin. Pharmacol.